Objective:

Transplantation, nephron sparing surgery, or renal vascular surgery, where renal blood flow is interrupted called as renal ischemia. Reperfusion is necessary for re-oxygenation of ischemic tissue. However, reperfusion is known to cause additional cellular damage. Sildenafil citrate is the first-found phosphodiesterase type 5 (PDE5) inhibitor. In this study; Sildenafil citrate in the early stages of experimental kidney ischemia-reperfusion injury.

Material and Methods:

Twenty-eight Wistar rats were gathered in to 4 groups (n=7) Serum samples were taken from each subject for measurement of Malondialdehyde (MDA) and creatine before transaction. We perform all rats right nephrectomy. In group 1 (sham group) rats was not take sildenafil and was not perform ischemia procedure. In group 2 (sildenafil group;) rats only take orally sildenafil. In group 3 (Ischemia group) micro vascular clamp placed left renal artery for 45 min. There was not take sildenafil. In group 4 (treatment group) micro vascular clamp located left renal artery and rats take orally sildenafil. After 4 hours ischemia time, blood samples were taken to measure serum creatine and MDA. And then all animals were sacrificed.

Results:

There was no statistical difference among groups for MDA and creatine levels. Also statistical difference among groups was not detect for histopathological assessment.

Conclusion:

Sildenafil citrate claimed that it has positive effect for ischemia reperfusion damage in long term use. In our study, statistically meaning difference is not detected in tissue MDA, serum MDA and creatine levels. Meaning difference among groups is not observed in still histopathological assess. As a result; we think that sildenafil citrate has no therapeutic effect in the early period of renal ischemia reperfusion injury.

Keywords: kidney, ischemia-reperfusion damage, sildenafil citrate